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Abstract
Objective
Detailed data are lacking on influenza burden in the United Kingdom (UK). The objective of
this study was to estimate the disease burden associated with influenza-like illness (ILI) in
the United Kingdom stratified by age, risk and influenza vaccination status.
Methods
This retrospective, cross-sectional, exploratory, observational study used linked data from
the General Practice Research Database and the Hospital Episode Statistics databases to
estimate resource use and cost associated with ILI in the UK.
Results
Data were included from 156,193 patients with1 general practitioner visit with ILI. There
were 21,518 high-risk patients, of whom 12,514 (58.2%) were vaccinated and 9,004
(41.8%) were not vaccinated, and 134,675 low-risk patients, of whom 17,482 (13.0%) were
vaccinated and 117,193 (87.0%) were not vaccinated. High-risk vaccinated patients were
older (p<0.001) and had more risk conditions (p<0.001). High-risk (odds ratio [OR] 2.16) or
vaccinated (OR 1.19) patients had a higher probability of >1 general practitioner visit com-
pared with low-risk and unvaccinated patients. Patients who were high-risk and vaccinated
had a reduced risk of >1 general practitioner visit (OR 0.82; p<0.001). High-risk individuals
who were also vaccinated had a lower probability of ILI-related hospitalisation than individu-
als who were high-risk or vaccinated alone (OR 0.59). In people aged65 years, the mor-
tality rate was lower in vaccinated than unvaccinated individuals (OR 0.75). The cost of
ILI-related GP visits and hospital admissions in the UK over the study period in low-risk vac-
cinated patients was £27,391,142 and £141,932,471, respectively. In low-risk unvaccinated
patients the corresponding values were £168,318,709 and £112,534,130, respectively.
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Conclusions
Although vaccination rates in target groups have increased, many people are still not receiv-
ing influenza vaccination, and the burden of ILI in the United Kingdom remains substantial.
Improving influenza vaccination uptake may have the potential to reduce this burden.
Introduction
Influenza is an acute self-limiting viral disease which, in the majority of cases, is inconvenient
but generally not serious. However, seasonal influenza can cause severe illness, hospitalisations
and deaths, especially in those who are at ‘high risk’ due to age or underlying chronic health
problems.
There are three types of influenza virus, Type A, Type B and Type C [1]; only A and B cause
significant disease in humans [2]. Influenza A, of which there are currently two subtypes circu-
lating, H1N1 and H3N2 [3], is responsible for seasonal epidemic and occasional pandemic
activity. Influenza B, which currently has two antigenically distinct lineages, Yamagata and
Victoria, is responsible for outbreaks particularly in institutional settings.
Influenza can be prevented by vaccination. Annual vaccination against seasonal influenza is
recommended for high-risk groups, including people aged 65 years or more and people with
chronic health conditions [4], and the United Kingdom (UK) recently extended vaccination
recommendations to include children [5,6].
Although several studies have previously estimated the burden of illness attributable to
influenza in the UK [7–9], they have some limitations. For example, one did not include hospi-
tal data and thus is expected to have underestimated the burden of influenza [7], and others
did not link hospital and general practice databases [8,9] or collect vaccination and risk status
[8]. There is considerable disparity in estimates of influenza mortality derived from previous
studies [10]. Furthermore, data are lacking on the burden of illness stratified by risk status,
complication status (with or without complications of influenza recorded) or vaccination sta-
tus. A recent review of cost-of-illness studies in influenza worldwide identified no UK studies
reporting national cost-of-illness estimates, and only a few studies on the cost of influenza in
specific population groups (children) [11]. Thus, although the burden of influenza in England
has been shown to be substantial, accounting for 11,199 hospital admissions and 400 deaths
annually in patients not in a clinical risk group, and 6,054 hospital admissions and 1,406 deaths
annually in patients in a clinical risk group [9], it has not been described in sufficient detail.
To provide a more detailed understanding of the burden of influenza-like illness (ILI) to
healthcare resources in the UK, we have conducted a large database analysis using linked hos-
pital and general practice databases to quantify primary and secondary resource use and costs
associated with ILI. To our knowledge, this is the first study to use linked hospital and general
practice databases to assess the burden of illness in both primary and secondary care in ILI in
the UK. The primary results of the study have been published elsewhere (Watkins et al., in
preparation). The objective of the present analysis was to examine resource use and costs by
vaccination and risk status.
Materials and Methods
This was a retrospective, cross-sectional, observational study using data extracted from UK
databases for the period 21 January 2001 to 31 March 2009 inclusive. The study period ended
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immediately before the 2009 H1N1 influenza pandemic. The data were divided into influenza
seasons running from 1 April to 31 March inclusive, e.g. 1 April 2001 to 31 March 2002, etc.
The study thus covered nine influenza seasons. The first season (2000–2001) ran from the
study start date on 1 January 2001 to 31 March 2001. Influenza circulated from week 4 in 2001
according to surveillance data from the Health Protection Agency (HPA), so the study would
have captured the majority of the influenza cases in the 2000–2001 season, although it is possi-
ble that there were some cases in the last weeks of 2000 for which data were not collected.
Data collection
Influenza cases are generally not virologically confirmed in routine UK clinical practice [8],
and influenza or ILI is rarely recorded specifically in medical notes [12]. Thus, neither a specific
diagnosis of influenza/ILI nor virologically confirmed influenza could be used as the selection
method. The General Practice Research Database (GPRD) codes general practitioner (GP) con-
sultations using clinical READ codes. The proportion of patients in the GPRD with linked data
in the Hospital Episode Statistics (HES) dataset is 58.8%, and the linked patients are represen-
tative of the whole GPRD population [13]. Since this study was initiated, the GPRD has
changed its name and is now known as The Clinical Practice Research Datalink (CPRD).
Data on patients who had at least one GP consultation with a READ code describing influ-
enza, acute upper or lower respiratory tract infection, or ILI were extracted from the linked
GPRD-HES dataset for the period between 21st January 2001 and 31st March 2009 inclusive.
Consultations coded with any of these READ codes that occurred during periods of peak influ-
enza circulation were attributed to ILI (S1 File). Consultations coded with any of these specific
READ codes that occurred during periods of peak influenza circulation were attributed to ILI.
Peak influenza periods were those weeks when influenza A and influenza B were circulating,
identified by regression analysis of surveillance data on circulating influenza and other respira-
tory pathogens obtained from the UK Health Protection Agency (HPA) for the period Novem-
ber 2002 to December 2008 [14], using the same technique as Pitman et al. [8] (described
further below). Patients with GP consultations coded with a relevant READ code during these
influenza periods were included in the study if they also had a minimum of 14 days observation
before and after the index event; and at least 1 year observation before diagnosis.
Patients were stratified by age group (<5 years; 5–18 years, 19–49 years, 50–64 years,
65+ years), by risk status (high-risk as defined by National Institute for Health and Care Excel-
lence [15] or Department of Health [16] criteria, or low-risk) and by influenza vaccination sta-
tus. Patients were categorised as ‘vaccinated’ if they had a record of an influenza vaccination in
the same winter flu season as the index episode.
Data on GP consultations and hospital admissions were extracted from the linked GPRD
and HES dataset (S1 File). If there were two GP consultations recorded for a patient on the
same day, only one was counted. Data were observed for 14 days after the GP consultation to
identify any hospital admission for influenza or complications following influenza. Only the
first episode of each hospitalisation was retained in the dataset, as this was more likely to be
related to the cause of the admission rather than to subsequent complications.
Mortality data were identified from the linked GPRD-HES dataset, where mortality was
recorded by the GP or at hospital discharge. Population estimates were obtained from the
Office for National Statistics (ONS), using mid-year estimates for the resident population for
2001–2009 [17].
Surveillance data on circulating influenza and other respiratory infections were obtained
from the UK HPA for the period November 2002 to December 2008, which were grouped into
UK Influenza Burden by Vaccination Status
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flu weeks (periods of approximately 4–5 weeks). Data on the mismatch between the influenza
vaccine and circulating influenza virus strains/lineages were obtained from the HPA [14].
Outcomes
The primary outcome measures were mortality, resource use (only those GP consultations and
hospital admissions with READ codes related to the episode were included) and cost associated
with influenza in primary and secondary care, stratified by age group, complication status, vac-
cination status and risk status. This paper presents data on vaccination uptake, and resource
use, cost and mortality by vaccination status and degree of mismatch. Other results of the
study have been published elsewhere (Watkins et al., in preparation). Medications prescribed
were limited to include items such as antipyretics, analgesics, antivirals, nasal decongestants,
antihistamines and antibiotics. Furthermore, only those encounters related with an episode
were included in the analysis any routine visits or unrelated encounters were excluded.
Cost data
Unit costs for hospitalisations, GP consultations and outpatient visits were obtained from the
Personal Social Services Research Unit database for 2011 [18]. Resource use data were com-
bined with unit cost data to estimate total costs, from the perspective of the UK National
Health Service. All costs were expressed in £ (pounds sterling) using 2011 costs.
Data analysis
Regression analysis was used to estimate the proportion of GP consultations, hospitalisations
and deaths potentially attributable to each pathogen, using the same technique as Pitman et al.
[8], previously described by Ryan et al [19].
The observed temporal trends in laboratory confirmed reports of agents that could poten-
tially cause influenza/acute respiratory infection/ILI was compared with the number of events
under consideration (GP consultations, hospital episodes, or mortality) over the same time
period. The latter was used as the dependent variable of a multiple regression. The independent
variables were the weekly number of national laboratory reports (HPA data, 2001–2009) for
adenovirus, coronavirus, influenza A, influenza B,Mycoplasma pneumoniae, parainfluenza,
respiratory syncytial virus, and rhinovirus. Laboratory reports were not age stratified as this
would have resulted in too few individuals in certain classes.
This method of linear regression uses the number of laboratory reports for pathogen i in
week j, Lij and a background number of national laboratory reports to estimate the regression
coefficients αj that fit into the equation: Yj = c + Siαi  Lij, Yj indicating the independent vari-
able (weekly number of national laboratory reports aggregated over all age groups). A multivar-
iable regression, assuming normality of the error terms, was performed. The initial model
included all the organisms as explanatory variables. The significance of each organism was
assessed, and if the p value was>0.1 or the variable was significant but the resulting coefficient
negative (which is biologically implausible) the variable was discarded from the model. The
validity of the final model was assessed in terms of the proportion of the variation it explained
(R2), the significance of the joint relationship between the observed and independent variables
in each model (i.e. the probability that R differed significantly from zero), and the impact of
changes in the model specification.
Regression analysis was used to assess the relationship between burden and the degree of
mismatch between the influenza vaccine and the circulating influenza virus strains in each
year. Multivariate analysis was used to uncover structure within the data and those factors con-
tributing to excess burden. This was based on knowledge of the source data once it has been
UK Influenza Burden by Vaccination Status
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obtained and processed. Generalised linear models were fitted to characterise any association
between baseline characteristics and burden
Vaccinated and unvaccinated patients categorised as high-risk were compared using an inde-
pendent samples t-test with age and number of risk conditions as the test variables. A similar
analysis was undertaken in patients categorised as not high-risk, using age as the test variable.
To extrapolate from the database sample to the total UK population, a multiplying factor
was calculated. The annual average total UK population during the study period was
60,313,633, using ONS mid-year estimates for the resident population for 2001–2009 [17]. The
annual average number of patients in the linked GPRD-HES database population was
1,662,953 between 2000 and 2009, calculated from the GPRD-HES data extract. Dividing the
database population by the total UK population gives a multiplying factor of 36.3. Results from
the database were then multiplied by this factor to estimate the total burden in the whole of the
UK. The same factor was used for all patient groups, as age-specific, complication-specific and
risk-specific populations were not available. No adjustments for demographics were made.
Results
Study population
The linked dataset included 156,193 patients with at least one GP consultation for ILI (defined
as described in the Methods). The mean age was 42.7 years and 55% were women. The demo-
graphic characteristics of the study population have been published elsewhere (Watkins et al.,
in preparation). Table 1 shows the breakdown of general physician visit by READ code.
Vaccination uptake
Table 2 shows the percentage of patients in each risk group vaccinated by year. Elderly patients
(age 65+ years) had the highest uptake rates, and uptake rates generally increased between the
beginning and end of the study period in each risk group.
Table 1. General Practitioner Visit Break down by READCode.
READ Code Count of patient visits Description
H27z.11 125769 Flu like illness
H27..00 14359 Inﬂuenza
H2z..00 5789 Pneumonia or inﬂuenza NOS
16L..00 3809 Inﬂuenza-like symptoms
H27z.12 2050 Inﬂuenza like illness
H27z.00 1937 Inﬂuenza NOS
H2. . .00 1805 Pneumonia and inﬂuenza
H2y..00 203 Other speciﬁed pneumonia or inﬂuenza
H27y100 151 Inﬂuenza with gastrointestinal tract involvement
H271z00 101 Inﬂuenza with respiratory manifestations NOS
H270000 68 Inﬂuenza with bronchopneumonia
H271000 66 Inﬂuenza with laryngitis
H271100 31 Inﬂuenza with pharyngitis
H270.00 21 Inﬂuenza with pneumonia
H270.11 15 Chest infection—inﬂuenza with pneumonia
H270z00 11 Inﬂuenza with pneumonia NOS
H271.00 6 Inﬂuenza with other respiratory manifestation
F030800 1 Encephalitis due to inﬂuenza-speciﬁc virus not identiﬁed
H27y000 1 Inﬂuenza with encephalopathy
doi:10.1371/journal.pone.0134928.t001
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Table 3 shows the percentage of patients vaccinated each year by age and risk status. Overall,
there were 21,518 high-risk patients, of whom 12,514 (58.2%) were vaccinated and 9,004
(41.8%) were not vaccinated. There were 134,675 low-risk patients of whom 17,482 (13.0%)
were vaccinated and 117,193 (87.0%) were not vaccinated.
In the high-risk group, the mean age of the vaccinated group was 65.1 years (standard devia-
tion [SD] 16.5) compared with 48.2 years (SD 20.4) in the unvaccinated group (p<0.001). The
mean number of risk conditions in the vaccinated group was 1.29 (SD 0.60), compared with 1.15
(SD 0.45) in the unvaccinated group (p<0.001). In the patients without risk conditions, vacci-
nated patients were also older than unvaccinated patients (mean 64.6 years [SD 17.3] compared
with mean 36.6 years [SD 16.8], p = 0.003). Vaccinated patients were therefore statistically signif-
icantly different from unvaccinated patients, as they were older and had more risk conditions.
This should be taken into account when considering outcomes in the different groups.
Resource use in low-risk patients
Table 4 shows the number and cost of ILI-related hospital admissions, GP consultations and
outpatient visits in low-risk patients by vaccination and complication status. Data on the abso-
lute numbers of ILI-related admissions, GP consultations and outpatient visits can be found in
S1 Table, and data on hospital admissions stratified by the route of admission (via accident and
emergency, GP referral or other routes) can be found in S2 Table.
In low-risk patients, unvaccinated patients used more GP and outpatient resources than vacci-
nated patients, reflecting the large number of unvaccinated low-risk cases in the database. Sec-
ondary care resource use was more evenly split, with slightly higher total resource use and cost in
the group of vaccinated patients than in the group of unvaccinated patients. This is consistent
with the older age of vaccinated patients compared with the unvaccinated group. Extrapolated to
the UK, the cost of ILI-related GP visits and hospital admissions over the study period in low-
risk vaccinated patients was £27,391,142 and £141,932,471, respectively. In low-risk unvaccinated
patients the corresponding values were £168,318,709 and £112,534,130, respectively.
Secondary care resource use was concentrated in cases of influenza with complications
recorded, regardless of vaccination status.
Resource use in high-risk patients
Table 5 shows the number and cost of ILI-related hospital admissions, GP consultations and
outpatient visits in high-risk patients by vaccination and complication status. Data on the
Table 2. Percentage of patients with a vaccination record each year, by risk group.
Year All
High
Risk
Respiratory Central
Nervous
System
Diabetes Chronic
Heart
Disease
Liver
Disease
Renal
Disease
Compromised
Immune System
Age 65
+ years
Not high risk
and aged <65
years
2001 43.6% 40.5% 40.7% 55.7% 49.2% 32.8% 54.8% 52.6% 65.4% 14.3%
2002 48.2% 43.1% 44.8% 60.5% 52.2% 35.3% 58.9% 55.8% 70.9% 15.0%
2003 51.5% 47.6% 48.4% 67.3% 57.7% 35.3% 65.3% 59.9% 76.0% 15.3%
2004 55.9% 51.1% 52.4% 74.3% 61.1% 40.0% 68.4% 67.1% 79.4% 15.3%
2005 61.4% 53.2% 54.5% 80.5% 67.5% 47.7% 72.6% 73.3% 84.5% 17.4%
2006 58.1% 64.7% 50.5% 77.8% 64.7% 50.0% 70.4% 66.4% 81.3% 15.0%
2007 59.1% 51.3% 54.2% 80.2% 65.6% 52.2% 72.3% 69.9% 80.3% 14.8%
2008 59.4% 51.6% 55.8% 79.2% 65.7% 53.7% 74.8% 71.3% 78.4% 15.0%
2009 61.2% 54.0% 56.0% 80.2% 67.6% 62.5% 77.6% 68.8% 75.9% 18.3%
doi:10.1371/journal.pone.0134928.t002
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Table 3. Vaccination status by age, risk group and year.
Inﬂuenza Year (April—March) Non-vaccinated Vaccinated
Age group Risk status Total N N % N %
2001 Overall 18,591 14,903 80.2% 3,688 19.8%
<5 years Not At Risk 373 368 98.7% 5 1.3%
At Risk 30 29 96.7% 1 3.3%
5–18 years Not At Risk 2,095 2,065 98.6% 30 1.4%
At Risk 145 122 84.1% 23 15.9%
19–49 years Not At Risk 8,821 8,474 96.1% 347 3.9%
At Risk 651 481 73.9% 170 26.1%
50–64 years Not At Risk 2,887 2,352 81.5% 535 18.5%
At Risk 570 291 51.1% 279 48.9%
>64 years Not At Risk 2,104 515 24.5% 1,589 75.5%
At Risk 915 206 22.5% 709 77.5%
2002 Overall 16,110 13,384 83.1% 2,726 16.9%
<5 years Not At Risk 400 399 99.8% 1 0.3%
At Risk 25 25 100.0% 0 0.0%
5–18 years Not At Risk 1,973 1,952 98.9% 21 1.1%
At Risk 111 91 82.0% 20 18.0%
19–49 years Not At Risk 7,485 7,213 96.4% 272 3.6%
At Risk 578 423 73.2% 155 26.8%
50–64 years Not At Risk 2,658 2,291 86.2% 367 13.8%
At Risk 557 269 48.3% 288 51.7%
<64 years Not At Risk 1,529 519 33.9% 1,010 66.1%
At Risk 794 202 25.4% 592 74.6%
2003 Overall 23,734 19,930 84.0% 3,804 16.0%
<5 years Not At Risk 675 674 99.9% 1 0.1%
At Risk 28 27 96.4% 1 3.6%
5–18 years Not At Risk 2,979 2,932 98.4% 47 1.6%
At Risk 157 128 81.5% 29 18.5%
19–49 years Not At Risk 10,909 10,568 96.9% 341 3.1%
At Risk 816 607 74.4% 209 25.6%
50–64 years Not At Risk 4,194 3,666 87.4% 528 12.6%
At Risk 779 404 51.9% 375 48.1%
<64 years Not At Risk 2,029 672 33.1% 1,357 66.9%
At Risk 1,168 252 21.6% 916 78.4%
2004 Overall 13,159 10,256 77.9% 2,903 22.1%
<5 years Not At Risk 193 192 99.5% 1 0.5%
At Risk 13 13 100.0% 0 0.0%
5–18 years Not At Risk 1,055 1,032 97.8% 23 2.2%
At Risk 51 36 70.6% 15 29.4%
19–49 years Not At Risk 6,070 5,817 95.8% 253 4.2%
At Risk 534 339 63.5% 195 36.5%
50–64 years Not At Risk 2,396 2,029 84.7% 367 15.3%
At Risk 529 210 39.7% 319 60.3%
<64 years Not At Risk 1,414 391 27.7% 1,023 72.3%
At Risk 904 197 21.8% 707 78.2%
(Continued)
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Table 3. (Continued)
Inﬂuenza Year (April—March) Non-vaccinated Vaccinated
Age group Risk status Total N N % N %
2005 Overall 20,905 16,678 79.8% 4,227 20.2%
<5 years Not At Risk 271 265 97.8% 6 2.2%
At Risk 8 8 100.0% 0 0.0%
5–18 years Not At Risk 1,948 1,910 98.0% 38 2.0%
At Risk 122 87 71.3% 35 28.7%
19–49 years Not At Risk 9,877 9,491 96.1% 386 3.9%
At Risk 818 530 64.8% 288 35.2%
50–64 years Not At Risk 3,843 3,289 85.6% 554 14.4%
At Risk 806 351 43.5% 455 56.5%
<64 years Not At Risk 1,930 484 25.1% 1,446 74.9%
At Risk 1,282 263 20.5% 1,019 79.5%
2006 Overall 18,015 14,299 79.4% 3,716 20.6%
<5 years Not At Risk 266 264 99.2% 2 0.8%
At Risk 5 5 100.0% 0 0.0%
5–18 years Not At Risk 2,520 2,453 97.3% 67 2.7%
At Risk 133 94 70.7% 39 29.3%
19–49 years Not At Risk 8,108 7,707 95.1% 401 4.9%
At Risk 634 397 62.6% 237 37.4%
50–64 years Not At Risk 3,085 2,587 83.9% 498 16.1%
At Risk 659 257 39.0% 402 61.0%
<64 years Not At Risk 1,510 344 22.8% 1,166 77.2%
At Risk 1,095 191 17.4% 904 82.6%
2007 Overall 18,960 15,214 80.2% 3,746 19.8%
<5 years Not At Risk 224 222 99.1% 2 0.9%
At Risk 8 6 75.0% 2 25.0%
5–18 years Not At Risk 1,755 1,710 97.4% 45 2.6%
At Risk 89 60 67.4% 29 32.6%
19–49 years Not At Risk 9,257 8,912 96.3% 345 3.7%
At Risk 664 435 65.5% 229 34.5%
50–64 years Not At Risk 3,407 2,951 86.6% 456 13.4%
At Risk 762 315 41.3% 447 58.7%
<64 years Not At Risk 1,454 354 24.3% 1,100 75.7%
At Risk 1,340 249 18.6% 1,091 81.4%
2008 Overall 20,743 16,863 81.3% 3,880 18.7%
<5 years Not At Risk 244 243 99.6% 1 0.4%
At Risk 8 8 100.0% 0 0.0%
5–18 years Not At Risk 1,523 1,488 97.7% 35 2.3%
At Risk 66 43 65.2% 23 34.8%
19–49 years Not At Risk 10,223 9,870 96.5% 353 3.5%
At Risk 670 441 65.8% 229 34.2%
50–64 years Not At Risk 4,145 3,679 88.8% 466 11.2%
At Risk 783 342 43.7% 441 56.3%
<64 years Not At Risk 1,752 478 27.3% 1,274 72.7%
At Risk 1,329 271 20.4% 1,058 79.6%
(Continued)
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absolute numbers of ILI-related admissions, GP consultations and outpatient visits can be
found in S1 Table, and data on hospital admissions stratified by the route of admission (via
accident and emergency, GP referral or other routes) can be found in S3 Table.
In high-risk patients, the group of vaccinated patients used more resources in primary and
secondary care, compared with the group of unvaccinated patients. This is consistent with the
older age and higher number of risk conditions in vaccinated than unvaccinated patients. As
was the case in low-risk patients, secondary care resource use was concentrated in cases of
influenza with complications recorded, regardless of vaccination status. Extrapolated to the
UK, the cost of ILI-related GP visits and hospital admissions over the study period in high-risk
vaccinated patients was £21,241,118 and £193,730,761, respectively. In high-risk unvaccinated
patients the corresponding values were £15,283,283 and £82,189,349, respectively.
Mortality
Table 6 shows the number of ILI-related deaths by vaccination status. Overall, more deaths
were observed in vaccinated than unvaccinated patients. This is consistent with the systematic
difference between vaccinated and unvaccinated individuals, as vaccinated individuals were
older and more fragile with more risk conditions than unvaccinated individuals. However,
among the group aged 65 years or more, the mortality rate among vaccinated individuals was
25% (odds ratio [OR] 0.75; 95% confidence interval [CI] 0.65 to 0.88; p<0.001) lower than in
unvaccinated individuals (3.3% of the age category and 4.3% of the age category, respectively)
(Table 6).
Mismatch analysis
Table 7 shows the circulating virus strains, influenza B vaccine lineages, and the degree of
matching between the vaccine and the circulating B lineage in each year of the study, from
HPA data. There was a mismatch between the vaccine and circulating influenza B virus lineage
in five of the ten years, and the two influenza B lineages co-circulated in three of the ten years.
The season 2005–2006 also had a very high circulation of influenza B, with influenza B
accounting for 70% of the circulating influenza that season.
There was a trend for influenza B mismatched seasons to be associated with peaks in ILI-
related GP visits (Fig 1A). The season with highest mismatch and highest influenza B
Table 3. (Continued)
Inﬂuenza Year (April—March) Non-vaccinated Vaccinated
Age group Risk status Total N N % N %
2009 Overall 5,976 4,670 78.1% 1,306 21.9%
<5 years Not At Risk 71 71 100.0% 0 0.0%
At Risk 3 3 100.0% 0 0.0%
5–18 years Not At Risk 497 486 97.8% 11 2.2%
At Risk 22 15 68.2% 7 31.8%
19–49 years Not At Risk 2,626 2,540 96.7% 86 3.3%
At Risk 165 90 54.5% 75 45.5%
50–64 years Not At Risk 1,232 1,080 87.7% 152 12.3%
At Risk 255 98 38.4% 157 61.6%
<64 years Not At Risk 668 194 29.0% 474 71.0%
At Risk 437 93 21.3% 344 78.7%
doi:10.1371/journal.pone.0134928.t003
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circulation, 2005–2006, was clearly associated with a peak in ILI-related GP visits (Fig 1A). The
highest rate of ILI-related deaths occurred in 2007–2008 and the second highest in 2005–2006,
both influenza B mismatched seasons (Fig 1B). ILI-related hospital admissions showed a simi-
lar pattern (Fig 1C).
Hospital admissions were highly correlated with GP visits (correlation coefficient 0.893 for
influenza A, 0.789 for influenza B and 0.715 for others), and mortality was highly correlated
with hospitalisation (correlation coefficient 0.884 for influenza B, 0.870 for influenza A, and
0.632 for others).
Table 5. Resource use in high-risk patients.
Vaccinated Non-Vaccinated
Overall
Inﬂuenza
Inﬂuenza with
complications
recorded
Inﬂuenza
without
complications
recorded
Overall
Inﬂuenza
Inﬂuenza with
complications
recorded
Inﬂuenza
without
complications
recorded
N % N % N % N % N % N %
Inpatient Admissions (All)
Had  1 hospital admission 503 4.0% 503 4.0% 0 0.0% 222 2.5% 219 2.4% 3 * 0.0%
Had  1 hospital admission (UK) 18,243 18,243 0 8,052 7,943 109
Mean number of unique admissions
(SD)
1.2 (0.53) 1.2 (0.53) - - 1.2 (0.51) 1.2 (0.51) 1 (0.0)
Mean length of stay (SD) 12.9 (5.9) 12.9 (5.9) - - 12.4 (19.5) 12.6 (19.6) 4 (3.6)
Mean total cost (SD) £5,341,498
(£1,078,996)
£5,341,498
(£1,078,996)
- - £2,266,105
(£1,514,544)
£2,271,538
(£1,501,739)
£8,232 (£0)
Mean total cost (SD) (UK) £193,730,761
(£39,134,100)
£193,730,761
(£39,134,100)
- - £82,189,349
(£54,930,988)
£82,386,399
(£54,466,563)
£298,566 (£0)
GP Surgery Visits
Had  1 GP surgery visit 12,514 100% 1,807 14.4% 10,707 85.6% 9,004 100% 1,225 13.6% 7,779 86.4%
Had  1 GP surgery visit (UK) 453,870 65,538 388,332 326,566 44,430 282,137
Mean number of GP Surgery visits
(SD)
1.3 (0.65) 1.9 (1.0) 1.2 (0.49) 1.3 (0.62) 1.8 (0.98) 1.2 (0.49)
Mean (SD) total costs £585,655
(£292,828)
£123,599
(£65,052)
£462,542
(£188,871)
£421,387
(£200,969)
£79,380
(£43,218)
£336,053
(£137,222)
Mean (SD) total costs (UK) £21,241,118
(£10,620,577)
£4,482,811
(£2,359,371)
£16,775,933
(£6,850,161)
£15,283,283
(£7,288,944)
£2,879,033
(£1,567,473)
£12,188,304
(£4,976,904)
GP Prescriptions
Had  1 prescription 10,454 83.5% 1,454 11.6% 9,000 71.9% 6,398 71.1% 985 10.9% 5,413 60.1%
Had  1 prescription (UK) 379,156 52,735 326,421 232,049 35,725 196,324
Mean number of prescriptions
obtained (SD)
5.6 (5.1) 6.1 (6.1) 5.5 (4.9) 3.6 (3.9) 3.6 (4.1) 3.6 (3.9)
Average cost per script £1.28 (£4.50) £1.95 (£5.64) £1.13 (£4.18) £1.19 (£4.33) £1.47 (£4.53) £1.12 (£4.27)
Out Patient Clinic Care
Had  1 OP Clinic visit 106 0.8% 42 0.3% 64 0.5% 74 0.8% 29 0.3% 45 0.5%
Had  1 OP Clinic visit (UK) 3,845 1,523 2,321 2,684 1,052 1,632
Mean number of OP clinic visit(SD) 1.1 (0.31) 1.1 (0.33) 1.1 (0.29) 1.1 (0.7) 1.0 (0.0) 1.2 (0.91)
Mean (SD) total costs £17,140
(£4,830)
£6,791
(£2,037)
£10,349
(£2,728)
£11,966
(£7,615)
£4,263 (£0) £7,938 (£6,020)
Mean (SD) total costs (UK) £621,651
(£175,179)
£246,303
(£73,880)
£375,348
(£98,942)
£433,995
(£276,188)
£154,615 (£0) £287,903
(£218,339)
GP, general practitioner; OP, outpatient; SD, standard deviation; UK, extrapolated to UK population
*Review of the records indicated that these patients had been mis-coded and had complications
doi:10.1371/journal.pone.0134928.t005
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Multivariate analysis
Table 8 shows the logistic regression coefficients for the likelihood of>1 GP visit, hospital
admission and mortality. High-risk patients and patients who had been vaccinated had a
higher probability of>1 ILI-related GP visit, compared with those who were not high-risk or
Table 6. Mortality by vaccination status and age.
Parameter All Inﬂuenza without complications
recorded
Inﬂuenza with complications
recorded
N Deaths Mortality % N Deaths Mortality % N Deaths Mortality %
Vaccinated
All Patients 29,996 633 2.1% 26,855 434 1.6% 3,141 199 6.3%
All Patients (UK) 1,087,925 22,958 974,004 15,741 113,921 7,218
Mean Age (SD) 64.8 64.5 (16.9) 67.1 (17.4)
Age Categories
<5 23 0 0.0% 20 0 0.0% 3 0 0.0%
5–18 537 1 0.2% 481 1 0.2% 56 0 0.0%
19–49 4,571 16 0.4% 4,153 16 0.4% 418 0 0.0%
50–64 7,086 32 0.5% 6,456 19 0.3% 630 13 2.1%
65+ 17,779 584 3.3% 15,745 398 2.5% 2,034 186 9.1%
Unvaccinated
All Patients 126,197 549 0.4% 118940 456 0.4% 7,257 93 1.3%
All Patients (UK) 4,577,038 19,912 4,313,834 16,539 263,204 3,373
Mean Age (SD) 37.5 37.4 (17.2) 39.3 (19.3)
Age Categories
<5 2,822 9 0.3% 2,585 9 0.3% 237 0 0.0%
5–18 16,704 28 0.2% 15,827 28 0.2% 877 0 0.0%
19–49 74,335 184 0.2% 70,327 177 0.3% 4,008 7 0.2%
50–64 26,461 74 0.3% 24,934 62 0.2% 1,527 12 0.8%
65+ 5,875 254 4.3% 5,267 180 3.4% 608 74 12.2%
SD, standard deviation; UK, extrapolated to UK population
doi:10.1371/journal.pone.0134928.t006
Table 7. Mismatch between vaccine lineages and circulating influenza B lineages (HPA data).
Distribution A & B Vaccine lineage Distribution within B Matching within B
Season Inﬂuenza A Inﬂuenza B B-lineage Victoria Yamagata
2000–2001 37% 63% Yamagata 0% 100% 100%
2001–2002 97% 3% Yamagata 0% 100% 100%
2002–2003 51% 49% Victoria 100% 0% 100%
2003–2004 99.6% 0% Victoria 0% 100% 0%
2004–2005 85% 15% Yamagata 17% 83% 83%
2005–2006 30% 70% Yamagata 99% 1% 1%
2006–2007 99% 1% Victoria 33% 67% 33%
2007–2008 64% 36% Victoria 0% 100% 0%
2008–2009 90% 10% Yamagata 94% 6% 6%
2009–2010 99% 1% Victoria 100% 0% 100%
Average 75% 25% 44% 56% 52%
doi:10.1371/journal.pone.0134928.t007
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had not been vaccinated. The OR for vaccinated patients was 1.19 (95% CI 1.11 to 1.28;
p<0.001) and the OR for high-risk patients was 2.16 (95% CI 2.02 to 2.28; p<0.001). However,
there was an interaction such that patients who were high-risk and vaccinated had a reduced
risk of>1 GP visit, with an OR of 0.82 (95% CI 0.75 to 0.91; p<0.001). There was no apparent
age interaction, so these effects were relevant for all age groups.
High-risk individuals who were also vaccinated had a lower probability of ILI-related hospi-
talisation than individuals who were high-risk or vaccinated alone (OR = 0.59; 95% CI 0.46 to
0.75; p<0.001). In years with influenza B mismatch, there was a statistically significant increase
in the odds of hospital admission (OR = 1.2; 95% CI 1.07 to 1.35; p<0.001). Patients who were
high-risk had a higher probability of ILI-related death during the study period (OR = 1.46; 95%
CI 1.25 to 1.69; p<0.001), and patients who were vaccinated had a lower probability of death
during the study period (OR = 0.78; 95% CI 0.66 to 0.92; p<0.01).
Discussion
The present study builds on previous investigations of the burden of ILI in the UK [7,8] in sev-
eral ways. To our knowledge, this is the first time that linked primary care and hospital
Fig 1. Number of (A) GP visits, (B) deaths and (C) hospitalisations by influenza week and pathogen.
‘Flu week’ indicates the year (first four digits) and range of weeks (last four digits), e.g. ‘20024044’ = 2002,
weeks 40–44. GP, general practitioner.
doi:10.1371/journal.pone.0134928.g001
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Table 8. Logistic regression coefficients for the risk of >1 general practitioner visit, hospitalisation andmortality.
All ages Coefﬁcient SE t value Pr(>|t|)
Likelihood of >1 GP visit in the 3 months after inﬂuenza diagnosis
(Intercept) -2.280 0.078 -29.190 0.000
Age  1 year -0.233 0.085 -2.730 0.006
Age 2–4 years -0.315 0.078 -4.040 0.000
Age 5–18 years -0.090 0.076 -1.180 0.238
Age 19–49 years Reference age group
Age 50–64 years 0.193 0.083 2.340 0.020
Age  65 years 0.063 0.083 0.750 0.451
Female 0.144 0.020 7.340 0.000
Manifested inﬂuenza 0.241 0.066 3.640 0.000
Hospital Event 1.262 0.063 20.010 0.000
High risk patient 0.764 0.031 24.570 0.000
Vaccinated 0.177 0.036 4.990 0.000
High risk & Vaccinated -0.193 0.048 -4.030 0.000
%Adenovirus 0.386 0.057 6.740 0.000
%Parainﬂuenza 0.732 0.139 5.280 0.000
% inﬂuenza B -0.302 0.082 -3.690 0.000
%Coronavirus -2.808 1.001 -2.810 0.005
High risk & Vaccinated -0.252 0.050 -5.030 0.000
Likelihood of hospital admission during the study period
(Intercept) -6.158 0.107 -57.680 0.000
Age  1 year 2.199 0.425 5.180 0.000
Age 2–4 years 1.799 0.201 8.930 0.000
Age 5–18 years 0.331 0.152 2.180 0.029
Age 19–49 years Reference age group
Age 50–64 years 0.699 0.102 6.850 0.000
Age  65 years 1.903 0.108 17.600 0.000
Female -0.307 0.060 -5.140 0.000
Manifested inﬂuenza 1..2276 0.103 11.900 0.000
Vaccine B mismatch 0.186 0.058 3.200 0.001
High-risk 1.174 0.096 12.250 0.000
Vaccinated 0.613 0.100 6.110 0.000
High-risk & Vaccinated -0.533 0.128 -4.160 0.000
% adenovirus 0.816 0.166 4.920 0.000
% parainﬂuenza 1.517 0.361 4.200 0.000
Likelihood of death during the study period
(Intercept) -5.094 0.392 -13.000 0.000
Age  1 year -1.096 0.495 -2.210 0.027
Age 2–4 years -0.497 0.392 -1.270 0.204
Age 5–18 years -0.318 0.394 -0.810 0.419
Age 19–49 years Reference age group
Age 50–64 years 1.310 0.397 3.300 0.001
Age  65 years 2.822 0.389 7.250 0.000
Female -0.200 0.070 -2.870 0.004
Manifested 1.234 0.107 11.540 0.000
High-risk 0.376 0.077 4.910 0.000
Vaccinated -0.246 0.084 -2.940 0.003
(Continued)
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databases have been used to estimate the burden of ILI. Furthermore, this is the first study to
report quantitative data for ILI burden by complication status (with complications recorded or
without complications recorded), age, risk and vaccination status.
Influenza vaccination uptake increased over the study period, but vaccination still failed to
reach 20–25% of people aged 65 years and older. In England, the target rate for influenza vacci-
nation in 2011–2012 was 75% in people aged 65+ years and 60% in other at-risk groups,
increasing to 75% in 2013/2014 [20]. Our study indicates that the vaccination uptake rates
achieved in the elderly population were close to the target range. However, vaccination uptake
rates in other at-risk groups were generally exceedingly low compared with the 2013/2014 tar-
get of 75%, except in a few conditions such as diabetes and renal disease. Improving vaccina-
tion uptake rates in younger age groups with risk conditions, and further improving
vaccination uptake in the elderly, may have the potential to reduce the considerable burden of
ILI in the UK. Our analysis demonstrates that vaccinated high-risk individuals have better out-
comes than high-risk unvaccinated individuals.
Most ILI cases occurred in individuals who were not categorised as high-risk, and who were
not vaccinated. Over 117,000 such patients visited a GP and 534 were admitted to hospital in
the study population, at an estimated cost of over £4 million and over £3 million, respectively.
Scaled up to the whole UK population, this would be equivalent to over £168 million for GP
visits and over £112 million for hospital admissions. This raises the possibility that mass annual
vaccination could potentially have medical and economic benefits, by reducing the burden of
influenza cases in individuals who are not in groups currently targeted for vaccination. Univer-
sal influenza vaccination was introduced in Ontario, Canada, in 2000 and has been associated
with reductions in influenza-related mortality and healthcare use, compared with targeted vac-
cination programmes in other provinces [21]. It has been suggested that mass vaccination
could be cost-saving in the USA [22].
Vaccinated patients differed significantly from unvaccinated patients, being older and with
more risk conditions. This pattern is well known [23], and is to be expected from current gov-
ernment policy, which targets elderly and/or high-risk groups for influenza vaccination. It is
consistent with the observed pattern of higher resource use in vaccinated patients in the high-
risk group in the present study; since vaccinated individuals were older and had more risk con-
ditions than unvaccinated individuals, they are likely to have more fragile health and thus to
need more healthcare. As vaccinated and unvaccinated groups are significantly different, out-
comes cannot be directly compared and the data should be interpreted with caution. The only
population in which vaccinated and unvaccinated groups could be compared is the sub-group
aged 65 years and older, as according to current policy all individuals in this age group should
receive seasonal influenza vaccination. Among this group, the ILI-related mortality rate among
vaccinated individuals was 25% lower than the mortality rate among unvaccinated individuals.
This is consistent with a protective effect of influenza vaccination. The effect size was similar to
that reported by previous studies in this population group, which have reported reductions of
Table 8. (Continued)
All ages Coefﬁcient SE t value Pr(>|t|)
Complications 0.970 0.083 11.690 0.000
% inﬂuenza A -0.841 0.177 -4.750 0.000
% RSV -1.051 0.214 -4.910 0.000
GP, general practitioner; RSV, respiratory syncytial virus, SE, standard error
doi:10.1371/journal.pone.0134928.t008
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33–62% in hospitalisations, 27–39% in hospitalisations for acute and chronic respiratory illness
and 39–54 in all-cause mortality [24–26].
Multivariate analysis indicated that patients categorised as high-risk had a disproportionate
risk of hospitalisation. However, high-risk individuals who had also been vaccinated had a
lower risk of hospitalisation than individuals who were high-risk alone. Similarly, patients who
were high-risk had a higher probability of>1 GP visit, whereas patients who were high-risk
and vaccinated had a lower probability of>1 GP visit. These findings suggest that vaccination
may help to reduce the risk of hospitalisation and additional GP visits in high-risk groups. This
demonstrates the clear benefit of vaccination of high-risk individuals and the rationale for
ensuring that coverage in this group of individuals be reinforced, as coverage in those younger
than 65 years is below target. Low vaccination coverage places individuals at risk of serious
complications and death because they are not being vaccinated against influenza. However,
although our results show clearly that vaccinated high-risk patients in the database had lower
rates of additional GP visits and hospitalisations than unvaccinated high-risk patients in the
database, there may be potential for confounding by differences in health-seeking behaviour
that could not be captured in the database or accounted for in the analysis. For example, sur-
veys in adults with asthma [27] and parents of high-risk children [28] at single UK GP practices
have identified lack of awareness, barriers to access and health beliefs as factors influencing
influenza vaccine uptake. Such factors could have the potential to confound our results if they
also affect patients’ readiness to seek treatment (for example, patients who wait until severe
symptoms develop before presenting for medical attention may require higher levels of inter-
vention than patients who present early). Our analysis would not be able to identify such
potential confounding factors, and this is a limitation of the study. A recent case-control study
using GPRD data in people at low risk for influenza in the UK found that influenza vaccination
reduced the risk of influenza (OR 0.74, 95% CI 0.60, 0.91) when given within 4 months before
seasonal influenza outbreaks [29]. However, despite the authors’ attempt to minimise con-
founding, they identified a residual confounding effect in that a group of people in the study
with annual vaccinations in multiple years were also consistently more likely to develop influ-
enza than those who received fewer annual vaccinations [29]. This may indicate that this group
had predisposing medical conditions that made them simultaneously more likely to seek influ-
enza vaccination and also at higher risk of influenza.
As per our assumption that the circulation data from the HPA was reflective of the strain
circulation in the community, which is a limitation of our study, influenza B GP visits, hospita-
lisations and deaths showed peaks in influenza seasons with high influenza B activity and vac-
cine mismatch. The correlation coefficients show that for influenza B, deaths were more closely
correlated with hospitalisations than hospitalisations with GP visits. For influenza A and other
respiratory infections, hospitalisations were more closely correlated with GP visits than deaths
with hospitalisation. The multivariate analysis also showed a statistically significant increase in
the odds of hospitalisation in years with vaccine influenza B mismatch. In seasons with a mis-
match between the vaccine lineage and the circulating influenza lineages, individuals may
receive less clinical benefit from vaccination than anticipated, because the vaccine provides
limited or no protection against the mismatched virus lineage. This suggests that improving
vaccine protection against influenza B in mismatched years could be of value. Quadrivalent
influenza vaccination provides protection against both influenza B lineages, which have started
to co-circulate in recent years, and should therefore improve protection.
It should be noted that the mismatch analysis depends on an implicit assumption that the
HPA surveillance data are representative of cases of respiratory infection seen in GP practices
and hospitals nationally. However, the HPA data are derived from sentinel practices, which
may differ from the more general pool of GP practices from which the GPRD data are derived.
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It is possible that using the HPA data to attribute cases between the various respiratory viruses
could over- or under-estimate the proportion of infections due to each pathogen, and this is a
limitation of the study.
A further limitation of the study is that complication status was assessed according to
whether complications were recorded in the database. If any patients had complications that
were not recorded, they could potentially have been mis-coded as having influenza without
complications. To explore this possibility we investigated the full records of the small number
of patients who were admitted to hospital despite having no complications of influenza
recorded in the database. This showed that although the patients had no secondary diagnosis
codes (and were therefore classed as having no complications), they in fact had complications
such as pneumonia or other respiratory manifestations. Coding errors such as these form a nat-
ural limitation to any retrospective database study, as even a comprehensive database cannot
capture all possible information.
Our data are likely to underestimate the true burden of ILI in the UK, because the years
included in the study all happened to be years of low influenza activity, as presented in the pri-
mary publication (Watkins et al., in preparation). Our data would also not have identified hos-
pital-acquired influenza infections. Furthermore, previous research has indicated that
hospitalisation for influenza may be a trigger for long-term health decline in elderly patients
[30]. Our study has not attempted to take such effects into account.
This study provides the most detailed quantitative data to date on the ILI burden in the UK.
It should help to narrow the considerable uncertainties in modelling the potential impact of
interventions [10].
Conclusions
Our results indicate that although vaccination rates in target groups have increased over the
study period, a substantial proportion of people are still not receiving influenza vaccination.
Improving the uptake of influenza vaccination among elderly people and other high-risk
groups has the potential to achieve substantial health benefits.
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